Clinical Trials

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grieve, A. P
Right arrow Articles by Krams, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grieve, A. P
Right arrow Articles by Krams, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical Trials, Vol. 2, No. 4, 340-351 (2005)
DOI: 10.1191/1740774505cn094oa

ASTIN: a Bayesian adaptive dose–response trial in acute stroke

Andrew P Grieve

Statistical Research and Consulting Centre, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK; Andy.P.Grieve{at}Pfizer.Com

Michael Krams

Clinical CNS, Pfizer Inc., Groton, Connecticut, CT 06340 USA

Understanding the dose–response is critical for successful drug development. We describe an adaptive design to efficiently learn about the dose–response and the ED95. A dynamic termination rule allows for early discontinuation either for efficacy or futility. The design was deployed in ASTIN, a phase II proof-of-concept trial of the neuroprotectant, neutrophil inhibitory factor (NIF), in acute stroke. We discuss the learning from this trial.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
B. Ameer
Novel Trial Design: A Report From the 19th Frontiers Symposium of ACCP
J. Clin. Pharmacol., July 1, 2008; 48(7): 793 - 798.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. Maloney, M. O. Karlsson, and U. S. H. Simonsson
Optimal Adaptive Design in Clinical Drug Development: A Simulation Example
J. Clin. Pharmacol., October 1, 2007; 47(10): 1231 - 1243.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. G. Maki, J. K. Wathen, S. R. Patel, D. A. Priebat, S. H. Okuno, B. Samuels, M. Fanucchi, D. C. Harmon, S. M. Schuetze, D. Reinke, et al.
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
J. Clin. Oncol., July 1, 2007; 25(19): 2755 - 2763.
[Abstract] [Full Text] [PDF]